


Supplementary Table 1. Including patients with first and last liver stiffness measures taken within 7 days of each other, variables associated with the change in liver stiffness measurements (kPa) in patients with CHC stratified by baseline kPa score.

Variables	All patients (n = 777)			Baseline kPa < 12 (n = 654)			Baseline kPa ≥ 12 (n = 123)		
	Effect estimate	95% CI	P	Effect estimate	95% CI	P	Effect estimate	95% CI	P
Antiviral treatment effect	-2.365	(-4.056, -0.673)	0.006	-1.496	(-2.786, -0.207)	0.023	-4.017	(-9.727, 1.693)	0.168
Baseline kPa	-0.544	(-0.683, -0.406)	< 0.001	-0.673	(-0.870, -0.476)	< 0.001	-0.587	(-0.799, -0.375)	< 0.001
Black race*	-0.616	(-1.604, 0.372)	0.221	-0.626	(-1.329, 0.077)	0.081	-1.845	(-6.545, 2.856)	0.442
Other race*	0.194	(-1.585, 1.973)	0.831	-0.662	(-1.865, 0.541)	0.281	3.574	(-4.213, 11.361)	0.368
Age ≥ 50 †	0.485	(-0.398, 1.368)	0.282	0.944	(0.332, 1.556)	0.002	-1.302	(-5.151, 2.546)	0.507
Female gender	-0.277	(-0.913, 0.359)	0.393	-0.253	(-0.754, 0.249)	0.323	-0.159	(-3.871, 3.553)	0.933
Diabetes	0.643	(-0.305, 1.592)	0.184	0.745	(-0.104, 1.593)	0.086	1.045	(-2.757, 4.847)	0.590
Current smoker	0.656	(-0.363, 1.675)	0.207	0.201	(-0.462, 0.865)	0.551	2.576	(-3.067, 8.219)	0.371
Former smoker	-0.019	(-0.961, 0.923)	0.969	-0.206	(-0.834, 0.422)	0.520	0.853	(-5.360, 7.067)	0.788
HIV co-infected	0.436	(-0.266, 1.138)	0.224	0.254	(-0.283, 0.792)	0.354	1.593	(-1.744, 4.929)	0.350
Baseline ALT (per 10 units)	0.019	(-0.048, 0.086)	0.574	0.018	(-0.038, 0.075)	0.529	0.046	(-0.270, 0.363)	0.774
Time between first and last TE (untreated group) (months)	-0.027	(-0.120, 0.066)	0.565	-0.013	(-0.100, 0.075)	0.775	0.029	(-0.340, 0.399)	0.877
Time between first and last TE (treated group) (months)^	0.017	(-0.051, 0.086)	0.620	0.008	(-0.044, 0.059)	0.772	0.011	(-0.209, 0.231)	0.920
Interaction of treatment and time	0.045	(-0.080, 0.169)	0.481	0.020	(-0.083, 0.123)	0.700	-0.018	(-0.429, 0.394)	0.932
Intercept	4.502	(2.677, 6.327)	< 0.001	4.725	(2.470, 6.981)	< 0.001	7.5	(0.177, 14.823)	0.045

* Effect of race estimated relative to white race as a reference

† Reference ages 18-49

^Estimated effect of time between first and last TE (treated group) is not directly included as a covariate in the model. Estimates for this row are derived from the antiviral treatment, time between first and last TE, and interaction terms.



Supplementary Figure 1 Change in liver stiffness between first and last transient elastography (TE) measurement in patients with chronic hepatitis C infection. Including patients with first and last liver stiffness measures taken within 7 days of each other, scatter plot illustrating the difference in liver stiffness (kPa) between the first and last TE measurement for patients who were treated (n = 405) and not treated (n = 372) for chronic hepatitis C infection during the study period. Circles correspond to values for individual patients. kPa, kilopascals.